stockrowArrowhead Pharmaceuticals, Inc.
ARWR Healthcare Biotechnology
Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024.
- Revenue
- +171.0%
- EPS
- −7.94%
- Free cash flow
- −15.4%
- Total debt
- +259.5%
Quarter to June 2026, against a year earlier
Follow ARWR
Alert me
Arrowhead Pharmaceuticals, Inc. (ARWR) EV/FCF
As of 5 November 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) trades at a EV/FCF of −100×. Over the past ten years it has ranged from −229× (September 2025) to 150× (June 2025); the current reading is higher than 8% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 25.2× | — |
| FY2024 | −3.4× | — |
| FY2023 | −8.4× | — |
| FY2022 | −16.9× | — |
| FY2021 | 41.5× | — |
| FY2020 | −37.5× | — |
| FY2019 | 14.8× | — |
| FY2018 | −31.5× | — |
| FY2017 | −8.3× | — |
| FY2016 | −5.4× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | −146× | — |
| Mar 2026 | −158× | — |
| Dec 2025 | 26.0× | 3.45% |
| Sep 2025 | 25.2× | — |
| 39 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| ARWR Arrowhead Pharmaceuticals, Inc. | −100× |
| TWST Twist Bioscience Corporation compare | −77.9× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −64.5× |
| SYRE Spyre Therapeutics, Inc. compare | −30.3× |
| CYTK Cytokinetics, Incorporated compare | −12.7× |
| KRYS Krystal Biotech, Inc. compare | 25.7× |
| CORT Corcept Therapeutics Incorporated compare | 37.7× |
| PTGX Protagonist Therapeutics, Inc. compare | 62.4× |
| CAI Caris Life Sciences,�Inc. compare | 181× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on ARWR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement